| scholarly article | Q13442814 |
| P356 | DOI | 10.1176/APPI.PSY.44.2.104 |
| P698 | PubMed publication ID | 12618532 |
| P2093 | author name string | Samuel B Ho | |
| Mark L Willenbring | |||
| Eric Dieperink | |||
| Paul Thuras | |||
| P433 | issue | 2 | |
| P921 | main subject | chronic hepatitis | Q62019625 |
| patient | Q181600 | ||
| ribavirin | Q421862 | ||
| P304 | page(s) | 104-112 | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | Psychosomatics | Q7256494 |
| P1476 | title | A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. | |
| P478 | volume | 44 |
| Q47677152 | "Look, I'm fit, I'm positive and I'll be all right, thank you very much": coping with hepatitis C treatment and unrealistic optimism. |
| Q33414941 | A Preliminary Study on the Relationship between Platelet Serotonin Transporter Functionality, Depression, and Fatigue in Patients with Untreated Chronic Hepatitis C. |
| Q37547057 | A Survey on the Prevalence of Depression in Blood Donors with Hepatitis C in Shiraz |
| Q34631232 | A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase |
| Q50580608 | A descriptive study of the relationship between mood disorders and hepatitis C treatment compliance: does nursing play a role? |
| Q37102263 | A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment |
| Q37395509 | A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder |
| Q35623581 | A pre-conditioning stress accelerates increases in mouse plasma inflammatory cytokines induced by stress |
| Q33413353 | All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. |
| Q41991403 | An Exploration of Depressive Symptoms in Hepatitis C Patients Taking Interferon-alpha: Increase in Sickness Behaviors but not Negative Cognitions |
| Q59796810 | Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression |
| Q26864986 | Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C interferon recipients without depression at baseline: a systematic review and meta-analysis |
| Q34330471 | Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder |
| Q28387292 | Association of Baseline Sleep Quality With Trajectories of Depressive Symptoms in Patients Undergoing Interferon Treatment |
| Q42239297 | Baseline Comorbidities Enhance the Risk of Treatment-Induced Depression in HCV-Infected Men: A Pilot Study |
| Q37032660 | Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. |
| Q43039554 | Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-α and ribavirin therapy: a prospective evaluation |
| Q37016316 | Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. |
| Q42198830 | Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trial. |
| Q36272273 | Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care |
| Q58769791 | Comments on the paper ?The effect of a herbal medicine (Mao-to) for the prevention of interferon-induced psychiatric complications in chronic hepatitis C: a pilot study? |
| Q33370676 | Complementary treatments of chronic viral hepatitis C |
| Q37439042 | Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality |
| Q40599927 | Depression and anxiety in patients receiving interferon-alpha: The role of illness perceptions. |
| Q27477533 | Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction |
| Q36183715 | Depression following pegylated interferon-alpha: characteristics and vulnerability |
| Q55050518 | Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study. |
| Q34225384 | Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks |
| Q35087836 | Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C. |
| Q35903305 | Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection |
| Q34129599 | Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. |
| Q90147568 | Evaluation of depression, anxiety and quality of life in hepatitis C patients who treated with direct acting antiviral agents |
| Q43042527 | Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study |
| Q36364200 | Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients |
| Q38286393 | Experiences of UK patients with hepatitis C virus infection accessing phlebotomy: A qualitative analysis. |
| Q46156497 | Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy |
| Q43479412 | Fatigue and depressive symptoms associated with chronic viral hepatitis patients’ health-related quality of life (HRQOL) |
| Q36373495 | Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C) |
| Q36059746 | Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy |
| Q27491342 | HIV/Hepatitis C Virus-Coinfected Virologic Responders to Pegylated Interferon and Ribavirin Therapy More Frequently Incur Interferon-Related Adverse Events Than Nonresponders Do |
| Q36658219 | Hepatitis C in people with mental illness: how big is the problem and how do we respond? |
| Q35574487 | Hepatitis C treatment of patients with bipolar disorder: a case series |
| Q51905365 | High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. |
| Q45115322 | IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity |
| Q50575247 | Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. |
| Q56917730 | Influence of healthcare-associated factors on the efficacy of hepatitis C therapy |
| Q27477998 | Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders |
| Q33750627 | Interferon-alpha Treatment of Hepatitis C Patients With Psychiatric Illness: Evidence-Based Risk-Benefit Assessment |
| Q34026599 | Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha |
| Q34603307 | Liver-targeting of interferon-alpha with tissue-specific domain antibodies |
| Q35237145 | Major depression during interferon-alpha treatment: vulnerability and prevention |
| Q34084151 | Major depressive disorder in hepatitis C: an open-label trial of escitalopram |
| Q43497594 | Management of Hepatitis C in HIV-infected Patients |
| Q37596596 | Managing depression during hepatitis C treatment |
| Q36987360 | Managing the neuropsychiatric complications of hepatitis C treatment |
| Q37055015 | Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. |
| Q41354841 | Missing the obvious: psychosocial obstacles in Veterans with hepatocellular carcinoma |
| Q35660841 | Molecular and contextual markers of hepatitis C virus and drug abuse. |
| Q36282281 | Neurobehavioral effects of interferon therapy |
| Q34081783 | Neuropsychiatric adverse effects of interferon-alpha: recognition and management |
| Q37110047 | Neuropsychiatric symptoms of hepatitis C. |
| Q34511200 | No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C |
| Q36327782 | Nutrition, psychoneuroimmunology and depression: the therapeutic implications of omega-3 fatty acids in interferon-α-induced depression |
| Q34795051 | Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users |
| Q34262438 | Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C. |
| Q48949896 | Persistent pro-inflammatory cytokines following the initiation of pegylated IFN therapy in hepatitis C infection is associated with treatment-induced depression |
| Q35090876 | Pharmacokinetic characteristics, pharmacodynamic effect and in vivo antiviral efficacy of liver-targeted interferon alpha |
| Q33816643 | Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment |
| Q45403636 | Pretreatment preparation and management of interferon-based therapy for hepatitis C virus infection. |
| Q51847669 | Prevalence of hepatitis C in two inpatient psychiatry populations. |
| Q45227683 | Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression |
| Q34365319 | Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial |
| Q43269486 | Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study |
| Q36383766 | Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management |
| Q33708662 | Psychiatric clearance for patients started on interferon-alpha-based therapies |
| Q36642912 | Psychiatric management of the hepatitis C patient. |
| Q34138808 | Psychiatric side effects of non-psychiatric drugs |
| Q35011072 | Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. |
| Q43041286 | Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C. |
| Q34073122 | Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics |
| Q40595654 | Risk factors and clinical characteristics of the depressive state induced by pegylated interferon therapy in patients with hepatitis C virus infection: A prospective study |
| Q37886673 | Risk factors for the development of depression in patients with hepatitis C taking interferon-α. |
| Q50571279 | Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection |
| Q45415714 | Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life |
| Q38255698 | Side effects of cytokines approved for therapy |
| Q45399537 | Singin' the blues: the downside of hepatitis C virus treatment |
| Q37808747 | Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update |
| Q50575290 | Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment |
| Q42260238 | The experience of hepatitis C treatment for people with a history of mental health problems: An interpretative phenomenological analysis |
| Q79209752 | The importance of depressive disorders in somatic medicine |
| Q37582072 | The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis. |
| Q34852990 | Toward an anti-inflammatory strategy for depression |
| Q49919112 | Trained innate immunity: a salient factor in the pathogenesis of neuroimmune psychiatric disorders. |
| Q37171783 | Transcriptomics in Interferon-α-Treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression |
| Q27491016 | Treat Early or Wait and Monitor? A Qualitative Analysis of Provider Hepatitis C Virus Treatment Decision-Making in the Context of HIV Coinfection |
| Q45332272 | Trend of depression and the use of psychiatric medications in U.S. Veterans with hepatitis C during interferon-based therapy |
| Q36475320 | Uncertainty, symptoms, and quality of life in persons with chronic hepatitis C |
| Q42919841 | Use of fMRI to predict psychiatric adverse effects of interferon treatment for Hepatitis C - preliminary report. |
| Q34001639 | Utility of the Beck Depression Inventory to screen for and track depression in injection drug users seeking hepatitis C treatment |
| Q51899124 | Widening the door: the evolution of hepatitis C treatment in patients with psychiatric disorders. |
| Q48612640 | Withdrawing interferon-α from psychiatric patients: clinical care or unjustifiable stigma? |
| Q81585317 | [Psychiatric disorders during treatment of chronic hepatitis C] |
Search more.